Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952591 | 0.85 | NLRP3 (0.55) | NLRP3LMNAALOX15CMA1 | |
| SCHEMBL23952040 | 0.84 | NLRP3 (0.47) | NLRP3LMNAALOX15 | |
| SCHEMBL23952041 | 0.84 | NLRP3 (0.63) | NLRP3LMNAALOX15CMA1 | |
| SCHEMBL23952044 | 0.84 | NLRP3 (0.47) | NLRP3LMNA | |
| SCHEMBL23952368 | 0.84 | NLRP3 (0.47) | NLRP3LMNAALOX15 | |
| SCHEMBL23952604 | 0.83 | NLRP3 (0.48) | NLRP3LMNAALOX15CMA1 | |
| SCHEMBL28970046 | 0.83 | NLRP3 (0.46) | NLRP3LMNAALOX15CMA1 | |
| SCHEMBL23952611 | 0.83 | NLRP3 (0.46) | NLRP3LMNAALOX15 | |
| SCHEMBL23952600 | 0.82 | NLRP3 (0.48) | NLRP3LMNAALOX15CMA1 | |
| SCHEMBL23952602 | 0.81 | NLRP3 (0.47) | NLRP3ALOX15CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885LMNA 2529/4885ALOX15 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.